Eli Lilly and Company (NYSE:LLY) Stock Price Down 3.8% – What’s Next?

Eli Lilly and Company (NYSE:LLY)’s stock price dropped 3.8% during trading on Thursday . The company traded as low as $1,012.57 and last traded at $1,032.5070. Approximately 4,171,949 shares were traded during trading, an increase of 38% from the average daily volume of 3,026,697 shares. The stock had previously closed at $1,073.29.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly announced a strategic, high‑profile partnership with Nvidia to build an AI drug‑discovery co‑innovation lab (reported as a $1B initiative). This reinforces long‑term R&D acceleration and secular growth optionality beyond GLP‑1s. Nvidia And Eli Lilly To Build $1 Billion AI-Powered Drug Discovery Lab
• Positive Sentiment: J.P. Morgan coverage and conference commentary highlighted continued GLP‑1 momentum and Q4 sales beats, supporting near‑term revenue visibility from Mounjaro/Zepbound. JPM Day 1: Obesity Front-and-Center, Q4 Sales Beats
• Positive Sentiment: Analysts remain constructive—Jefferies and other houses have reaffirmed Buy ratings and elevated price targets, underscoring continued conviction in Lilly’s incretin franchise and pipeline. Where is Eli Lilly and Company (LLY) Headed According to Analysts?
• Neutral Sentiment: JPM coverage also flagged Lp(a) programs as a longer‑duration cardiovascular growth vector—important for multi‑year upside but not immediate revenue. JPM26: Eli Lilly highlights Lp(a) drugs as cardiovascular growth focus
• Neutral Sentiment: Analyst/market pieces note that Mounjaro and Zepbound demand should support Q4 results despite pricing pressure—this is supportive for earnings but already priced into lofty multiples. How Will Mounjaro and Zepbound Sales Aid LLY’s Upcoming Q4 Results?
• Negative Sentiment: A compounding pharmacy (Strive Specialties) filed an antitrust suit alleging coordinated actions by Lilly and Novo Nordisk around GLP‑1 market dominance; litigation risk raises uncertainty around pricing, distribution and competitive behavior. Lilly, Novo sued over GLP‑1 drug dominance by compounding pharmacy
• Negative Sentiment: The FDA reportedly delayed its decision on Lilly’s oral obesity candidate (orforglipron), a setback that reduces the chance of near‑term incremental market share versus rivals and prompted immediate selling pressure. FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report
• Negative Sentiment: Market coverage tied the FDA delay to an intraday ~5% move downward and broader headlines explaining why LLY is down today—amplifying short‑term volatility. Eli Lilly Stock (LLY) Falls 5% After FDA Delays Decision on Company’s Weight-Loss Pill

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research report on Monday, December 1st. UBS Group started coverage on Eli Lilly and Company in a research report on Tuesday, January 6th. They set a “buy” rating and a $1,250.00 target price on the stock. Berenberg Bank increased their price target on Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a research note on Tuesday, December 2nd. Scotiabank began coverage on Eli Lilly and Company in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $1,165.00 price target for the company. Finally, Daiwa Capital Markets set a $1,230.00 price objective on shares of Eli Lilly and Company and gave the company a “buy” rating in a report on Tuesday, December 16th. Five investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $1,169.00.

Eli Lilly and Company Stock Down 3.8%

The firm has a market capitalization of $976.11 billion, a price-to-earnings ratio of 50.51, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The business has a fifty day moving average price of $1,047.15 and a two-hundred day moving average price of $867.23.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the prior year, the firm earned $1.18 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of Eli Lilly and Company by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 80,959,089 shares of the company’s stock valued at $61,771,785,000 after purchasing an additional 551,659 shares during the period. State Street Corp raised its position in shares of Eli Lilly and Company by 0.6% in the third quarter. State Street Corp now owns 34,726,558 shares of the company’s stock worth $26,496,364,000 after acquiring an additional 219,590 shares during the period. Capital Research Global Investors boosted its stake in shares of Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after acquiring an additional 4,332,008 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Eli Lilly and Company by 4.1% during the 3rd quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company’s stock valued at $11,112,164,000 after acquiring an additional 574,229 shares during the period. Finally, Laurel Wealth Advisors LLC grew its position in shares of Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after acquiring an additional 11,537,661 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.